Table 3.

Achieving viral suppression following albuvirtide-based dual therapy, by baseline HIV-1 RNA levels (Panel A) and treatment status (Panel B).

A
Duration of treatment	Viral Suppression with HIV-1 RNA < 40 copies/mL		P value‡
	Group A* N (%, 95%CI)	Group B† N (%, 95%CI)
2 wk	53 (66.3%, 54.8–76.5%)	28 (39.4%, 28.0–51.8%)	.001
4 wk	60 (75.0%, 64.1–84.0%)	35 (49.3%, 37.2–61.4%)	.0011
8 wk	72 (90.0%, 81.2–95.6%)	59 (83.1%, 72.3–91.0%)	.2118

B
Duration of treatment	Viral Suppression with HIV-1 RNA < 40 copies/mL		P value‡
	Treatment-naïve patients§ N (%, 95%CI)	Treatment-experienced patients∥ N (%, 95%CI)
2 wk	37 (42.5%, 32.0–53.6%)	44 (68.8%, 55.9–79.8%)	.0014
4 wk	44 (50.6%, 39.6–61.5%)	51 (79.7%, 67.8–88.7%)	.0003
8 wk	72 (82.8%, 73.2–90.0%)	59 (92.2%, 82.7–97.4%)	.0912

^*Group A (N = 80): Baseline HIV-1 RNA level <100,000 copies/mL.

^†Group B (N = 71): Baseline HIV-1 RNA level ≥100,000 copies/mL.

^‡P value of Chi-square test was determined by comparing the percentage difference between groups.

^§Treatment-naïve patients (N = 87).

^∥Treatment-experienced patients (N = 64).